George Goldsmith

George Goldsmith serves as the Chairman and Co-founder of a company focused on addressing mental health issues on a large scale through scientifically validated methods. He is deeply involved in the development of the investigational COMP360 psilocybin treatment, which is currently undergoing a global phase 3 program aimed at aiding individuals with treatment-resistant depression. Goldsmith upholds values such as compassion, boldness, rigour, and inclusivity in his work. He is dedicated to ensuring that therapies are accessible to all potential beneficiaries in a broad and equitable manner. Adhering to the highest standards of scientific integrity and rigour, he is committed to transparent practices, including the publication of all clinical study results—regardless of the outcome—and supports the publication of independent studies involving COMP360 psilocybin. His approach to clinical research is aligned with recommended scientific processes from regulatory agencies, and he actively collaborates with various stakeholders to advance science for better patient outcomes.